

## **Alchemia Expands Executive Leadership Team, Appointing Thomas Liquard as Chief Operating Officer**

BRISBANE, Australia: 16 December 2013 – Alchemia Limited, (ASX: ACL) a drug discovery and development company, announces today the appointment of Thomas Liquard as Chief Operating Officer, effective immediately. Mr. Liquard will be responsible for managing commercial and corporate development, in addition to assuming a range of other responsibilities across the organization.

“We are pleased to welcome someone of Thomas’ calibre to Alchemia”, said Charles Walker, CEO. “In addition to his deep understanding of 505(b)(2) regulation, which is of relevance to products derived from the HyACT technology, and experience in the field of oncology, Thomas brings significant pharmaceutical industry skills and experience to Alchemia and is an exceptional appointment to the Company as it looks to build value for the future.”

Mr Liquard said: “I am delighted to join Alchemia, one of the leading companies in the Australian biotechnology sector. With its late stage HA-Irinotecan program continuing to move forward and an advanced underlying technology platform in HyACT, this is truly an exciting time to join the company. I look forward to contributing to Alchemia’s development as we prepare to take our next transformative steps.”

Mr Liquard joins Alchemia following 7 years with Pfizer, Inc. in New York, where he held various commercial roles of increasing scope and responsibility, most recently as Senior Director, Portfolio Development Lead Emerging Markets for the Established Products (EP) portfolio. Prior to that appointment, Mr Liquard spent 3 years as a key member of the EP US Brands P&L Leadership Team where he engineered the group’s 505(b)(2) investment strategy, culminating in the \$700M acquisition of NextWave Pharmaceuticals, and where he also led the day-to-day business operations for the group. Mr Liquard also spent significant time in the New Product Planning and Portfolio Decision & Analysis organizations, where he was responsible for informing investment decisions on business development opportunities (licensing and M&A) and internal development programs across multiple therapeutic areas including oncology, CNS and metabolic diseases. Prior to joining Pfizer, Mr Liquard was Senior Consultant at Frankel Group, a strategy consultancy focused on the biotechnology and pharmaceutical industries. Mr Liquard holds an MBA from Columbia Business School and a Bachelor of Science degree from the University of Southern California.

Nathan Drona, Chairman of Alchemia, commented: “This is a key appointment at an important time for Alchemia. Thomas’ leadership qualities combined with his strategic thinking and relevant experience makes him an ideal person to help drive the company to success over the coming years. We are confident that the addition of Thomas to the senior management team will be valued by shareholders and employees alike.”

## About Alchemia – [www.alchemia.com.au](http://www.alchemia.com.au)

Alchemia is a drug discovery and development company with an FDA approved drug (fondaparinux), a late stage oncology product pipeline (Phase II and III) within its wholly owned subsidiary, Audeo Oncology, Inc. (Audeo), and a proprietary drug discovery platform, VAST.

Fondaparinux (a generic version of GlaxoSmithKline's Arixtra®) is an injectable anticoagulant approved in the US for the prevention and treatment of deep vein thrombosis (DVT) after knee or hip surgery. Alchemia's wholly-owned subsidiary, Audeo, is developing a suite of oncology drugs using its proprietary platform technology HyACT® which targets anti-cancer drugs to solid tumours. The most advanced HyACT drug, HA-Irinotecan, is in a Phase III clinical trial for the treatment of metastatic colorectal cancer with results expected in H1-CY2014. This product is also in two Phase II trials, the most recent in collaboration with Merck Serono in which HA-Irinotecan is being tested in combination with Erbitux® (cetuximab). The VAST technology is a drug discovery platform being developed in collaboration with world leading academics and is partnered with AstraZeneca AB.

### Contact

[www.alchemia.com.au](http://www.alchemia.com.au)

[www.audeooncology.com](http://www.audeooncology.com)

#### Alchemia Limited

Charles Walker  
Chief Executive Officer  
Alchemia Limited  
Tel: +61 7 3340 0200

#### Audeo Oncology, Inc.

Charles Walker  
Chief Executive Officer  
Audeo Oncology Inc.  
Tel: +61 7 3340 0200

#### Alchemia Limited

Rosemary Cummins  
Investor Relations  
Alchemia Limited  
Tel: +61 4 0959 6164

#### Media enquiries, Australia

Emma Power or Rudi Michelson  
Monsoon Communications  
+61 3 9620 3333  
[emmap@monsoon.com.au](mailto:emmap@monsoon.com.au)

#### Investor Relations USA

Laura Forman  
Blueprint Life Science Group  
+1 415 375 3340 Ext. 103  
[lforman@bplifescience.com](mailto:lforman@bplifescience.com)